Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Date:3/3/2010

A live webcast will be available to all interested parties through the Investors section of Angiotech's website: www.angiotech.com/investors

                       ANGIOTECH PHARMACEUTICALS INC.
                    CONSOLIDATED STATEMENTS OF OPERATIONS

                                      (Unaudited)                   (Audited)
                              Three months ended                  Year ended
                                     December 31,                December 31,
    -------------------------------------------------------------------------

                              2009          2008          2009          2008

    REVENUE
    Product sales,
     net               $    49,975   $    46,054   $   191,951      $190,816
    Royalty revenue         13,533        15,676        62,171        91,546
    License fees                53           352        25,556           910
    -------------------------------------------------------------------------
                            63,561        62,082       279,678       283,272
    -------------------------------------------------------------------------

    EXPENSES
    Cost of products
     sold                   29,010        23,622       104,616       101,052
    License and royalty
     fees                    2,494         2,774        10,431        14,258
    Research and
     development             6,175         7,723        23,701        53,192
    Selling, general
     and administration     22,402        21,381        81,504        98,483
    Depreciation and
     amortization            8,406         8,421        33,251        33,998
    In-process research
     and development 
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)...  Caris Life Sciences ® , a leading ... precision medicine, today announced the presentation of data ... of Caris Molecular Intelligence ® , the company,s ... identify targeted treatment options for patients with rare ... results of which are to be presented in ...
(Date:5/29/2015)... Seoul Semiconductor (CEO: Chung-hoon Lee, http://www.seoulsemicon.com ), ... announced that it will increase the global automotive ... and high reliable LED product line-up for the ... developed efficient and reliable LED packages for the ... headlamps to global auto makers. Seoul Semiconductor’s 14 ...
(Date:5/28/2015)... 28, 2015  Quest Diagnostics Incorporated (NYSE: DGX ... announced that it is scheduled to speak at the ... Steve Rusckowski , the company,s President and CEO, will ...  The presentation is scheduled for Tuesday, June 2, 2015 ... will be webcast live during the conference and will ...
(Date:5/28/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) ... report "Cell Therapy - Technologies, Markets and ... report describes and evaluates cell therapy technologies and ... important role in the practice of medicine. Hematopoietic ... bone marrow transplants. Role of cells in drug ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2
... July 11, 2011 MRIGlobal, an internationally recognized ... the U.S. and overseas, has appointed Richard A. Winegar, ... http://photos.prnewswire.com/prnh/20110711/DC32923 ) Dr. Winegar is ... in radiation biology and genetic toxicology.  As Principal Advisor ...
... WORCESTER, Mass. and TORONTO, July 11, 2011 ... announced today the publication of studies conducted at ... Ii-Key technology.  Antigen Express, Inc., the Company,s wholly-owned ... development of self-potentiating immunotherapeutic vaccines for cancer.  AE37, ...
... York, NY July 10, 2011 Researchers at ... them to engineer the index of refraction and fully ... possible for light (electromagnetic waves) to propagate from point ... through the artificial medium as if the medium is ...
Cached Biology Technology:MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science 2Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 2Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 3Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 4Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 5Light propagation controlled in photonic chips -- major breakthrough in telecommunications field 2
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... FP7 funded project IMPRESSIONS (Impacts and Risks from High-End Scenarios: ... from 13 to 15 January 2014 in Oxford, United Kingdom. ... 18 countries will join forces to answer one of the ... future of humankind and nature if climate continues to change ...
... of great current interest as chemical sensors, in ... David G. Cahill, a Willett Professor and head ... at the University of Illinois at Urbana-Champaign. "Applications ... of light at a different wavelength than the ...
... retina can be bombarded by reactive oxygen species in diabetes, ... ones and ruin vision. Now researchers have learned that ... marrow as well as the retinal cells themselves to cause ... players to signal the next event that causes the damage," ...
Cached Biology News:IMPRESSIONS: Advancing understanding of the consequences of high-end climate change 2IMPRESSIONS: Advancing understanding of the consequences of high-end climate change 3Understanding secondary light emission by plasmonic nanostructures may improve medical imaging 22 players produce destructive cascade of diabetic retinopathy 2
... Start Taq Monoclonal Antibody ... the onset of thermal ... and primer-dimer formation. When ... the antibody is quickly ...
... Human Pathogenic Viruses The ... (NCPV) preserves well characterised, authenticated ... secure facility, and NCPV is ... or nucleic acids derived from ...
... 5 Fluorescein 6-Fam, Hex, ... 3 Fluorescein Tamra Black Hole ... 6-Fam, Hex, Tet Tamra, Joe ... Health Research Institute, New York Double labelled ...
... easy to use Ascent Software ... members of the Ascent microplate ... clear and easy-to-follow approach with ... and highly sophisticated data handling, ...
Biology Products: